作者
Kate A Markey, Rachel D Kuns, Daniel J Browne, Kate H Gartlan, Renee J Robb, J Paulo Martins, Andrea S Henden, Simone A Minnie, Melody Cheong, Motoko Koyama, Mark J Smyth, Raymond J Steptoe, Gabrielle T Belz, Thomas Brocker, Mariapia A Degli-Esposti, Steven W Lane, Geoffrey R Hill
发表日期
2018/4/1
期刊
Clinical Cancer Research
卷号
24
期号
7
页码范围
1604-1616
出版商
American Association for Cancer Research
简介
Purpose: Allogeneic bone marrow transplantation (BMT) provides curative therapy for leukemia via immunologic graft-versus-leukemia (GVL) effects. In practice, this must be balanced against life threatening pathology induced by graft-versus-host disease (GVHD). Recipient dendritic cells (DC) are thought to be important in the induction of GVL and GVHD.
Experimental Design: We have utilized preclinical models of allogeneic BMT to dissect the role and modulation of recipient DCs in controlling donor T-cell–mediated GVHD and GVL.
Results: We demonstrate that recipient CD8α+ DCs promote activation-induced clonal deletion of allospecific donor T cells after BMT. We compared pretransplant fms-like tyrosine kinase-3 ligand (Flt-3L) treatment to the current clinical strategy of posttransplant cyclophosphamide (PT-Cy) therapy. Our results demonstrate superior protection from …
学术搜索中的文章
KA Markey, RD Kuns, DJ Browne, KH Gartlan, RJ Robb… - Clinical Cancer Research, 2018